Relationship Between Body Weight Change and Glycaemic Control with Tirzepatide Treatment in People with Type 2 Diabetes: A Post Hoc Assessment of the SURPASS Clinical Trial Programme
Diabetes Obes Metab. 2023;25:2553–2560
Given that improvements in glycaemic control may be linked to both weight-independent and weight-dependent mechanisms, it is of interest to understand how changes in glycaemia and weight seen with tirzepatide are related. This post hoc analysis assessed the relationship between HbA1c and body weight reductions with tirzepatide treatment (5, 10 or 15 mg) across the SURPASS clinical trial programme.
Consistent reductions in both HbA1c and body weight were observed in most participants treated with tirzepatide at doses of 5, 10 or 15 mg; however, some participants had improved HbA1c, but not weight loss. A statistically significant but modest association between HbA1c and body weight change was observed in some trials (SURPASS-2, SURPASS-3 and SURPASS-4), but not others. These findings suggest that both weight-independent and weight-dependent mechanisms are responsible for the tirzepatide-induced improvement in glycaemic control, and these require further study.
Keywords:
